No Data
Stocks hitting the upper or lower price limit in the afternoon session.
■Stock limit up: Fujikawa E&C<1775>, Saipet<269A>, SBI Saudi Arabia Stock Listed Investment Trust<3779>, Jay Escom Holdings<4598>, Delta-Fly Pharma<6391>, Kaji Tech<7901>, Matsumoto<7971>, Toyo Rikagaku<8732>, Money Partners Group■Stock limit down: RSC<4664>, EMPlus※Includes temporarily suspended upper and lower limits (indicative values)
Stocks that moved the previous day part 2: M&A Soken, Housecom, ROXX, etc.
Stock name <Code> 30-day closing price ⇒ Previous day comparison M&A Research <9552> 2408 -333M&A Advisor number revised plan, negative view. Hino Motors <7205> 406.1 -62.5 Negative view due to certification-related losses leading to significant final deficit forecast. Good Communication Asset <3475> 829 -79 Impact of rights distribution as a high-yield stock intensifies. Daiki Special Steel <5471> 1211 -116.5 Downward revision of full-year performance forecast. Medley <448
T&S G, LPF and others
Company <4055> Tian and S established a subsidiary <4598> DELTA-P, large exercise of 8th subscription rights (with exercise price adjustment clause), number of shares to be issued from 30th of mass exercise, 0.25 million shares <7091> LPF established a subsidiary.
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.
DELTA-P - significant increase, announces progress of clinical phase 1/2 trials of DFP-10917 and VEN.
Significant increase. After the close of trading on the 28th, the progress of clinical phases 1/2 trials of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when administered in low doses via sustained intravenous drip, is believed to have high safety, halt cancer cells in the G2/M phase, and induce apoptosis (programmed cell death). Therefore, it is expected to have a high synergistic effect with VEN (BCL-2 inhibitor). Currently, phase 1 clinical trials are being conducted, combining standard therapy with VEN and azacitidine.
Volume change rate ranking (9 o'clock) ~ Marudai Shokuhin, Sea You Sea, etc. are ranked.
In the volume change rate ranking, you can understand the interest of market participants, such as trends in speculation, by comparing the volume of the latest 5 days with the volume on the delivery day. Top Volume Change Rate [As of October 29, 9:32] (Comparison with the latest 5-day average volume) Stock Code Stock Name Volume 5-day Average Volume Volume Change Rate Stock Price Change Rate <3329> Toa Food 174,200 107,185.08 62.69% 0.0038% <3733> Soft
No Data
No Data